Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by barsaxon Nov 25, 2019 6:53pm
133 Views
Post# 30391251

RE:Resverlogix Announces Warrant Exercise Incentive Program

RE:Resverlogix Announces Warrant Exercise Incentive ProgramOdd.  I like it, and I don't like it.

We get cash for the short term.  Dilution? Yes.  But, its dilution that already existed under the current capital structure...i.e. warrants that would have been execised on any take-over.  It removes the over hang of  $100 - 150 million dollar financing.  Unless they are confident that post CTAD results will result in a higher secondary offering issue price.  Does it signal an outright sale?  i.e. we get the oxygen to take us through a negotiation (auction)  period with multiple suitors?  Or, it gets us to a point where the FDA gives us a breakthrough therapy drug designation....that would be a huge game changer (60 to 90 days I think)

In some ways, it just makes things a little more uncertain/cloudy....what's he playin' at?
Bullboard Posts